Patents by Inventor Robert J. Tressler

Robert J. Tressler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Carcinomas with a Combination of EGF-Pathway and Telomerase Inhibitors
    Publication number: 20150359883
    Abstract: A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.
    Type: Application
    Filed: August 31, 2015
    Publication date: December 17, 2015
    Inventors: Robert J. Tressler, Ning F. Go
  • Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
    Patent number: 9155753
    Abstract: A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: October 13, 2015
    Assignee: Geron Corporation
    Inventors: Robert J. Tressler, Ning F. Go
  • Combined telomerase inhibitor and gemcitabine for the treatment of cancer
    Patent number: 7989428
    Abstract: A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: August 2, 2011
    Assignee: Geron Corporation
    Inventors: Ning F. Go, Robert J. Tressler
  • Treatment of Carcinomas with a Combination of EGF-Pathway and Telomerase Inhibitors
    Publication number: 20100104586
    Abstract: A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.
    Type: Application
    Filed: March 6, 2008
    Publication date: April 29, 2010
    Applicant: Geron Corporation
    Inventors: Robert J. Tressler, Ning F. Go
  • Combined Telomerase Inhibitor and Gemcitabine for the Treatment of Cancer
    Publication number: 20100016407
    Abstract: A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.
    Type: Application
    Filed: October 30, 2007
    Publication date: January 21, 2010
    Applicant: Geron Corporation
    Inventors: Ning F. Go, Robert J. Tressler
  • Sulfated maltooligosaccharides with heparin-like properties
    Patent number: 5739115
    Abstract: A novel class of highly sulfated maltooligosaccharide having heparin-like activity is described, as well as methods for using these oligosaccharides to treat certain diseases including cancer, and retinopathies.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: April 14, 1998
    Assignee: Glycomed Incorporated
    Inventors: Peter Fugedi, David J. Tyrrell, Robert J. Tressler, Robert J. Stack, Masayuki Ishihara